Results 251 to 260 of about 365,877 (337)

Integrative bioinformatics identifies NSCLC biomarkers associated with LPS metabolism and circadian disruption. [PDF]

Transl Oncol
Chen Y, Zhao Y, Kong Q, Li Y, Jiang P, Fan L.   +5 more
europepmc   +1 more source

A new perspective on cancer treatment: the interaction and application prospect between ICIs and radiotherapy

Precision Radiation Oncology, EarlyView.
The combination of immune checkpoint inhibitors (ICIs) and radiotherapy synergistically enhances efficacy through an “antigen release‐immune activation” closed‐loop mechanism, significantly improving outcomes in solid tumors (e.g., lung cancer, melanoma).
Guiling Song, Lei Wang, Guopeng Zhao, Song Tan, Xin Liu, Xinghua Li   +5 more
wiley   +1 more source

Ubiquitination and deubiquitination as critical modulators of NSCLC tumorigenesis and drug resistance. [PDF]

Discov Oncol
Ramalingam PS, Afzal M, Rekha MM, Sahoo S, Pandey SN, Maji C, Goyal K, Ali H, Singh SK, Gupta G, Hussain MS, Balakrishnan P, Arumugam S.   +12 more
europepmc   +1 more source

Thoracic radiotherapy may enhance the survival of patients with low‐risk advanced lung adenocarcinoma based on protein biomarkers

Precision Radiation Oncology, EarlyView.
The prognosis of LUAD was significantly influenced by many clinical and protein biomarkers. A risk model was developed to help identify advanced LUAD patients who would benefit from thoracic radiotherapy, and thoracic radiotherapy just significantly improved the survival of low‐risk patients but not that of high‐risk.
Chunliu Meng, Fang Wang, Juan Wang, Jia Tian, Xue Li, Haijun Lu, Lujun Zhao, Ping Wang   +7 more
wiley   +1 more source

Clinical applications of antibody-drug conjugates in advanced non-small cell lung cancer. [PDF]

Front Immunol
Guo H, Xu Z, Li K, Guo C, Lin F, Pu Q, Wang G.   +6 more
europepmc   +1 more source

A sample size analysis of a mathematical model of longitudinal tumor volume and progression‐free survival for Bayesian individual dynamic predictions in recurrent high‐grade glioma

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 495-509, March 2025.
Abstract Patients with recurrent high‐grade glioma (rHGG) have a poor prognosis with median progression‐free survival (PFS) of <7 months. Responses to treatment are heterogenous, suggesting a clinical need for prognostic models. Bayesian data analysis can exploit individual patient follow‐up imaging studies to adaptively predict the risk of progression.
Daniel J. Glazar, Solmaz Sahebjam, Hsiang‐Husan M. Yu, Dung‐Tsa Chen, Menal Bhandari, Heiko Enderling   +5 more
wiley   +1 more source

Relapsed NSCLC

Oncology Times, 2004
openaire   +2 more sources

Unveiling miR-451a and miR-142-3p as prognostic markers in non-small cell lung cancer via small extracellular vesicle liquid biopsy. [PDF]

Clin Transl Med
Burdiel M, Arauzo-Cabrera A, Jiménez J, Moreno-Velasco R, Rodríguez-Antolín C, Pernía O, Madrid-Cardenas E, Higuera O, Gutiérrez-Sainz L, Yubero P, Villamayor J, Losantos-García I, Erill Sagalés N, González Rumayor V, de Castro J, de Ibáñez de Cáceres I, Vera O.   +16 more
europepmc   +1 more source

Mechanistic Learning for Predicting Survival Outcomes in Head and Neck Squamous Cell Carcinoma

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 540-550, March 2025.
ABSTRACT We employed a mechanistic learning approach, integrating on‐treatment tumor kinetics (TK) modeling with various machine learning (ML) models to address the challenge of predicting post‐progression survival (PPS)—the duration from the time of documented disease progression to death—and overall survival (OS) in Head and Neck Squamous Cell ...
Kevin Atsou, Anne Auperin, Jôel Guigay, Sébastien Salas, Sebastien Benzekry   +4 more
wiley   +1 more source

Review of Existing Approaches and Potential Role of Pharmacometrics in the Interpretation of Prognostic Circulating Serum Biomarkers in Advanced NSCLC. [PDF]

Clin Transl Sci
Ojara FW, Nassar YM, Geiger K, van Dyk M, Holdenrieder S, Joerger M, Kloft C.   +6 more
europepmc   +1 more source